Highest-materiality recent filing
BullFrog AI raises CEO salary to $600K, target bonus up to 50% of base
CEO Vininder Singh's base salary increased from $400K to $600K, effective June 11, 2026.
BullFrog AI regains Nasdaq minimum stockholders' equity compliance
Received Nasdaq notice on April 21, 2026 confirming compliance with $2.5M minimum equity requirement.
BullFrog AI sets June 11, 2026 annual meeting; shareholder proposal deadline April 29
Board established June 11, 2026 as date of the 2026 Annual Meeting of Stockholders.
BullFrog AI secures first commercial agreement with top 5 pharma; runway into late 2027
First commercial feasibility agreement with a top 5 global pharma for bfLEAP platform in MDD (market >$8B).
BullFrog AI raises $3.45M, now believes it meets Nasdaq equity requirement; avoids delisting
Raised aggregate net proceeds of at least $3.45M from ATM sales and equity line of credit facility.
BullFrog AI signs feasibility agreement with top-5 pharma for MDD target discovery
Agreement with top-5 global pharma (by 2025 revenue) for bfLEAP platform to identify novel drug targets in major depressive disorder (MDD).
BullFrog AI receives Nasdaq delisting notice for failing equity requirement; will request hearing
Nasdaq notified BullFrog AI on Feb 19, 2026 that it failed to meet extension terms for the $2.5M stockholders' equity requirement.
BullFrog AI receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified BullFrog AI on Feb 10, 2026 that common stock bid closed below $1.00 for 30 consecutive business days.
BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts
Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.
BullFrog AI stockholders approve reverse stock split and 750,000 share increase to equity plan
Approved reverse stock split at ratio between 1:2 and 1:15, with Board discretion on final ratio.
BullFrog AI receives Nasdaq extension until Feb 17, 2026 to meet equity requirement
Nasdaq granted BullFrog AI an extension until Feb 17, 2026 to regain compliance with $2.5M minimum stockholders' equity requirement.
Bullfrog AI reduces stockholder quorum to 33.33% and announces 2025 annual meeting results
Quorum for stockholder meetings reduced to 33.33% of shares outstanding, effective September 18, 2025.
BullFrog AI secures $10M equity line with Lincoln Park Capital
Entered purchase agreement with Lincoln Park Capital Fund for up to $10M of common stock over 36 months.
Stockholders' equity of $2,188,110 as of June 30, 2025 falls below Nasdaq's $2.5M minimum requirement.
BullFrog AI enters collaboration with Sygnature Discovery targeting $15M-$30M revenue through 2028
Collaboration with UK-based CRO Sygnature Discovery to offer BullFrog Data Networks to global biopharma clients.
Bullfrog AI enters $20M at-the-market equity distribution agreement with BTIG
Agreement with BTIG to sell up to $20M of common stock via ATM offerings at market prices.
Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial
Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.
bfLEAP platform enhanced with generative and causal AI exclusively licensed from Johns Hopkins APL, enabling explainable AI for target discovery and drug repositioning.
Bullfrog AI appoints Josh Blacher as CFO; prior CFO Dane Saglio passed away from cancer
Appoints Josh Blacher as CFO effective Dec 12, 2024 via consulting agreement with Danforth Advisors at $525/hour.
Bullfrog AI CFO Dane Saglio passed away on Dec 7; successor search underway
CFO Dane Saglio died on December 7, 2024; had served since September 2021.
Bullfrog AI raises $3.13M in registered direct offering and private placement
Sold 1,565,000 shares (or pre-funded equivalents) at $2.00/share plus warrants for same number.
Bullfrog AI appoints GSK veteran Dr. John Baldoni to Scientific Advisory Board
Dr. Baldoni brings 40+ years of pharma experience, including 29 years at GSK as SVP of Platform and Technology Sciences.
Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.
Bullfrog AI shareholders elect four directors and ratify auditor at annual meeting
Annual meeting held Sept 20, 2024; 63.02% quorum (4,947,894 shares represented).
Six of 68 gene clusters from LIBD brain dataset significantly enriched, pinpointing gene networks involved in bipolar disorder.
Bullfrog AI and Lieber Institute identify novel drug targets for neuropsychiatric disorders
Identified dozens of patient clusters for depression, schizophrenia, and bipolar disorder using bfLEAP AI platform.
Bullfrog AI CSO to present at Quantum Computing Symposium on April 15
CSO Tom Chittenden to present at Bio-IT World Conference in Boston on April 15, 2024 at 1 pm ET.
Fireside chat on March 5, 2024, featuring CEO Vin Singh and Lieber Institute CEO Daniel Weinberger.
Bullfrog AI Appoints Dr. Thomas W. Chittenden as Chief Scientific Officer
Dr. Chittenden appointed CSO effective February 26, 2024.
Bullfrog AI CEO to discuss early collaboration findings in fireside chat on March 5, 2024
CEO Vin Singh and LIBD's Daniel R. Weinberger will host a RedChip fireside chat on March 5, 2024 at 4:15 p.m. ET.
Bullfrog AI closes $5.7M public offering of stock and warrants
Gross proceeds of approx $5.7M from sale of 1,507,139 shares (or pre-funded warrants) and accompanying warrants.
Bullfrog AI appoints Dr. Gwenn Smith and Dr. Jeremiah Wala as scientific advisors
Dr. Gwenn Smith (Johns Hopkins) adds expertise in brain imaging, neuropsychiatry, and Alzheimer's disease.
Bullfrog AI collaboration yields potentially groundbreaking stratification of brain expression data
Early results from collaboration with Lieber Institute for Brain Development successfully stratified brain expression data from over 2,800 samples.
BullFrog AI receives Australian patent for mebendazole prodrugs including BF-223
Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole to treat cancers.
Bullfrog AI highlights 2023 achievements: $8.4M IPO, first revenue, key partnerships
Completed $8.4M IPO listing on Nasdaq in 2023; maintained low burn rate quarter to quarter.
Entered commercial agreement with Lieber Institute for Brain Development to commercialize AI/ML products from LIBD brain data.
14 candidates over-expressed in colon tumors identified using TCGA data; 3 are novel, 6 near-novel.
Bullfrog AI files 8-K on press release and investor data for preclinical study; details unavailable
Filed under Item 7.01; press release and investor presentation attached as exhibits.
Bullfrog AI files 8-K with press release; no specific details available
Press release attached as Exhibit 99.1; full text not included in provided document.
Bullfrog AI enters exclusive data partnership with Lieber Institute for Brain Development
Agreement signed Sep 8, 2023 gives Bullfrog AI access to LIBD's transcriptomic, genomic, epigenomic, and imaging brain data.
BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment
USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.
Bullfrog AI appoints Enrique García-Rivera as VP of Artificial Intelligence
Appointed Enrique García-Rivera, Ph.D., as Vice President of Artificial Intelligence to enhance bfLEAP AI platform.
BullFrog AI CEO Vin Singh to present at Gujarati Physicians Convention 2023 on June 10
CEO Vin Singh will present at the Gujarati Physicians Convention in Atlantic City, NJ on June 10, 2023 at 11 a.m. ET.
Bullfrog AI expands APL license to enhance bfLEAP AI platform capabilities
Expanded worldwide license with Johns Hopkins APL for patented technology powering bfLEAP AI platform.
Bullfrog AI regains Nasdaq listing compliance after filing late 10-Q
Received Nasdaq deficiency notice on May 23 for late Q1 2023 10-Q filing.
Bullfrog AI receives Nasdaq deficiency notice for late 10-K, files and regains compliance
Received Nasdaq deficiency letter on April 19, 2023 for failing to timely file Form 10-K (Rule 5250(c)(1)).
Gross proceeds of ~$8.43M from sale of 1,297,318 units at $6.50/unit; each unit includes one share, one tradeable warrant (exercise $7.80), and one non-tradeable warrant (exercise $8.125).
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Max materiality 0.80 · Median 0.55 · Most common event other_material